Suzhou Ribo Life Science (HKG:6938) said its underwriters fully exercised the overallotment option of its Hong Kong listing, and the stabilization period of its initial public offering ended on Thursday, Feb. 5, according to a same-day filing with the Hong Kong bourse.

Shares of the life sciences company fell over 3% in morning trade Friday.

The firm issued 4.7 million H shares at HK$57.97 apiece for additional net proceeds of HK$262.5 million.

The overallotment option was exercised after an equal number of shares were over-allocated in the international portion of the IPO.

The IPO's underwriters did not purchase or sell shares from the open market during the stabilization period.

The number of shares held by the public after the exercise of the overallotment option complied with Hong Kong's listing requirements, the firm said.